# HCA Healthcare Inc. (HCA) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $405.00, market value $87.7 billion.

## Valuation
- **P/E (trailing): 13.6×** (5-yr avg 13.6×, 3-yr avg 14.6×). HCA Healthcare Inc. trades at 13.6× trailing earnings, close to its own five-year average of 13.6×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 12.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.44**. A PEG of 0.44 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.1×**. Each dollar of revenue is priced at 1.1×.
- **Free-cash-flow yield: 6.8%** (5-yr avg 6.6%). Free cash flow equals 6.8% of the market value, in line with its five-year average of 6.6%. Above 5% is generally attractive.
- **Earnings yield: 7.4%**. The inverse of the P/E: 7.4% of the price is earned each year.

## Profitability
- **Net margin: 9.0%**. 9.0% of each dollar of sales reaches the bottom line.
- **Return on equity: -112.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: 11.3%**. Each dollar of assets produces 11.3% of profit.

## Growth
- **Revenue growth (1 yr): 7.1%** (3-yr 7.9%/yr, 5-yr 8.0%/yr). Revenue grew 7.1% over the last year, against 8.0% a year compounded over five years.
- **EPS growth (1 yr): 28.8%** (3-yr 13.9%/yr, 5-yr 21.0%/yr). Earnings per share rose 28.8%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 23.1%/yr**. Free cash flow has compounded at 23.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.77%** ($3.00 per share, trailing). HCA Healthcare Inc. yields 0.77%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 10%** (11% of free cash flow). 10% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 5**. 5 straight years of increases.
- **Dividend growth (5 yr): 22.6%/yr** (1-yr 9.1%). The dividend has compounded at 22.6% a year over five years, doubling roughly every 3 years at that pace.

## Analyst view
- **Analyst consensus: buy** (21 analysts). 21 analysts cover HCA Healthcare Inc.; the consensus is buy, with an average price target of $451.48 (+11% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -0.9%** (YTD -12.9%, 3-mo 9.1%). The shares are down 0.9% over twelve months including dividends.
- **From 52-week high: -27.2%** (14.4% above the low). Trading 27% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 0.19** (volatility 31%). Beta of 0.19 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HCA · Page: https://foliofundamentals.com/stocks/hca

Not investment advice.